

**Anti-MBL (human)****Mouse monoclonal antibody, biotinylated**

Subclass: IgG1/k

PRODUCT NO.

**HYB 131-01 B**

Clone: 3B6

---

SPECIFICITY	HYB 131-01 is specific for MBL (mannan-binding lectin) from human serum or plasma.
IMMUNOGEN	MBL purified from human donor plasma
TESTED APPLICATIONS	ELISA
SPECIES REACTIVITY (POSITIVE)	Human
SPECIES REACTIVITY (NEGATIVE)	Not determined
EPITOPE SPECIFICITY	The epitope is on the head-neck region of the MBL protein chain. Prior binding of the antibody is thought to block binding to carbohydrate. The epitope differs from that of HYB 131-10 and HYB 131-11.

---

## PRESENTATION

Content:	50 µL, 1 mg/mL +/- 15%. See Certificate of Analysis for details.
Preparation:	Biotinylated
Form:	Liquid
Solvent:	0.01 M phosphate buffer, pH 7.4, with 0.14 M NaCl and 15 mM sodium azide
Storage:	4-8°C without exposure to light. No precautions necessary during handling.

---

## APPLICATION

**ELISA:** HYB 131-01B is selective for normally oligomerized MBL when used as detection antibody in sandwich ELISA with HYB 131-01 coat (1, 2). HYB 131-01 can also be used in a manan assay, when coating with manan and using HYB 131-01B as the biotinylated detection antibody (3).

## TARGET

Mannan-binding lectin (MBL), also called mannose-binding lectin or protein, belongs to the C-type family of collectins, showing calcium-dependent binding to certain sugars. It consists of oligomers of triple-chain subunits and its binding and complement activating activities depend on its normal oligomerization. On binding to mannan-like microbial surface carbohydrates, MBL activates the complement system by means of its own lectin pathway, dependent on the MBL-associated serine proteases (MASPs). Because of the presence of different structural and promoter alleles in the population, 12% or more of the population have low concentrations (<50ng/mL) of normally oligomerized, functional MBL in plasma or serum.

## REFERENCES

1. Fiane AE, Videm V, Lingaas PS, Heggelund L, Nielsen EW, Geiran OR, Fung M, Mollnes TE (2003) Mechanism of Complement Activation and Its Role in the Inflammatory Response After Thoracoabdominal Aortic Aneurysm Repair. *Circulation* 108:849-856.
2. Dumestre-Perard C, Doerr E, Colombb MG, Loos M (2007) Involvement of complement pathways in patients with bacterial septicemia. *Mol Immunol* 44:1631-1638.
3. Ramos GP, Nishihara R, Maestri CA, Bichalho MG, Carvalho NS, Reason IM (2013) MBL serum Concentration in women with HPV presenting CIN III lesions. *Human Immunology* 74:67-69

## CONDITIONS

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.